Bart Vanhaesebroeck Selected Research

Cardiotoxicity

1/2019	PI3Kα Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction.
3/2015	PI3Kα is essential for the recovery from Cre/tamoxifen cardiotoxicity and in myocardial insulin signalling but is not required for normal myocardial contractility in the adult heart.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bart Vanhaesebroeck Research Topics

Disease

46	Neoplasms (Cancer) 02/2024 - 04/2003
10	Inflammation (Inflammations) 01/2020 - 04/2005
7	Insulin Resistance 01/2021 - 11/2012
7	Thrombosis (Thrombus) 01/2018 - 01/2010
6	Breast Neoplasms (Breast Cancer) 11/2022 - 04/2003
5	Infections 01/2023 - 08/2005
4	Obesity 01/2021 - 11/2009
4	Autoimmune Diseases (Autoimmune Disease) 01/2020 - 05/2011
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2013 - 08/2005
3	Hypersensitivity (Allergy) 05/2014 - 02/2008
3	Leukemia 05/2014 - 08/2012
2	Reperfusion Injury 06/2023 - 10/2017
2	Atrophy 01/2021 - 01/2019
2	Fatty Liver 01/2021 - 12/2015
2	Neuroinflammatory Diseases 10/2019 - 03/2014
2	Cardiotoxicity 01/2019 - 03/2015
2	Lymphopenia (Lymphocytopenia) 01/2017 - 10/2007
2	Glucose Intolerance 01/2016 - 05/2006
2	Carcinogenesis 10/2014 - 04/2008
2	Arthritis (Polyarthritis) 08/2014 - 04/2011
1	Vascular System Injuries 01/2023
1	Proliferative Vitreoretinopathy 01/2023
1	Muscular Atrophy (Muscle Atrophy) 01/2023
1	Congenital Structural Myopathies (Centronuclear Myopathy) 01/2023
1	Epiretinal Membrane (Epiretinal Membranes) 12/2022
1	Prostatic Neoplasms (Prostate Cancer) 01/2022
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2022
1	Olfactory Esthesioneuroblastoma (Esthesioneuroblastoma) 01/2022
1	Nasopharyngeal Neoplasms (Cancer of the Nasopharynx) 01/2021
1	Weight Loss (Weight Reduction) 01/2021
1	Hypoxia (Hypoxemia) 01/2021
1	Epstein-Barr Virus Infections 01/2021
1	Renal Cell Carcinoma (Grawitz Tumor) 10/2020
1	Neoplasm Metastasis (Metastasis) 10/2020
1	Ciliopathies 01/2020
1	Primary Immunodeficiency Diseases 01/2020
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2020
1	Hypothyroidism 01/2020
1	Cognitive Dysfunction 10/2019
1	Alzheimer Disease (Alzheimer's Disease) 10/2019

Drug/Important Bio-Agent (IBA)

28	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2023 - 04/2003
22	Protein Isoforms (Isoforms)IBA 10/2021 - 04/2003
16	Phosphotransferases (Kinase)IBA 02/2024 - 04/2008
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2005
8	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 02/2024 - 04/2008
7	EnzymesIBA 10/2020 - 10/2008
6	idelalisibIBA 12/2022 - 03/2014
6	Insulin (Novolin)FDA Link 01/2021 - 03/2009
5	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 11/2012
5	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2019 - 05/2006
4	CollagenIBA 12/2022 - 08/2014
4	AlpelisibIBA 10/2021 - 01/2019
3	LipidsIBA 01/2023 - 01/2010
3	somatostatin receptor 2IBA 01/2022 - 01/2021
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 10/2020
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2021 - 01/2018
3	LigandsIBA 10/2020 - 03/2009
3	CytokinesIBA 03/2014 - 02/2007
2	AntibodiesIBA 10/2020 - 06/2012
2	LeptinIBA 01/2016 - 11/2009
2	phosphatidylinositol 3,4,5-triphosphateIBA 10/2014 - 02/2012
2	IntegrinsIBA 08/2014 - 10/2011
2	AutoantibodiesIBA 06/2012 - 04/2011
2	Oncogene Proteins (Oncogene Protein)IBA 01/2012 - 01/2010
2	Immunoglobulin E (IgE)IBA 02/2008 - 10/2007
2	ChemokinesIBA 02/2007 - 04/2005
1	phosphatidylinositol 3-phosphateIBA 01/2023
1	Retinal Pigments (Pigments, Visual)IBA 01/2023
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2023
1	myotubularinIBA 01/2023
1	DNA (Deoxyribonucleic Acid)IBA 01/2023
1	Transforming Growth Factors (Transforming Growth Factor)IBA 12/2022
1	Sirolimus (Rapamycin)FDA Link 12/2022
1	Fibronectins (Fibronectin)IBA 12/2022
1	PI-3065IBA 11/2022
1	N- (1- (7- fluoro- 2- (pyridin- 2- yl)quinolin- 3- yl)ethyl)- 9H- purin- 6- amineIBA 01/2022
1	2- (3- (2- (1- isopropyl- 3- methyl- 1H- 1,2- 4- triazol- 5- yl)- 5,6- dihydrobenzo(f)imidazo(1,2- d)(1,4)oxazepin- 9- yl)- 1H- pyrazol- 1- yl)- 2- methylpropanamideIBA 01/2022
1	inavolisibIBA 01/2022
1	metabotropic glutamate receptor type 1IBA 01/2022
1	Androgen Receptors (Androgen Receptor)IBA 01/2022
1	Cell Surface ReceptorsIBA 09/2021
1	Sunitinib (Sutent)FDA Link 10/2020
1	Angiogenesis InhibitorsIBA 10/2020
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2020
1	AntigensIBA 10/2020
1	T Cell Transcription Factor 1IBA 10/2020
1	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 01/2020
1	IC 87114IBA 01/2020
1	duvelisibIBA 01/2020
1	Phenobarbital (Luminal)FDA Link 01/2020
1	copanlisibIBA 01/2020
1	Amyloid (Amyloid Fibrils)IBA 10/2019
1	Peptides (Polypeptides)IBA 10/2019

Therapy/Procedure

12	Therapeutics 01/2022 - 06/2006
3	Immunotherapy 10/2021 - 10/2016
1	Nerve Crush 06/2023
1	Drug Therapy (Chemotherapy) 09/2021
1	Radiotherapy 09/2021
1	Immunomodulation 10/2020
1	Oncolytic Virotherapy 01/2020